Ellex Expands Glaucoma Product Offering Through Acquisition of Canaloplasty Business
Ellex Medical Lasers Limited announced that it recently acquired the canaloplasty business of iScience Interventional, Inc., which comprises the iTrack 250 catheter and suture device for the treatment of mild to moderate glaucoma, according to a company news release.
“The new canaloplasty business will allow us to provide our existing customers with a complementary product offering for the treatment of glaucoma,” Tom Spurling, CEO of Ellex, said in a company news release. “We are also pleased to have existing iTrack 250 customers join Ellex. Combined with our [selective laser trabeculoplasty] laser product portfolio, which targets the early stage of glaucoma, iTrack 250 will enable Ellex to cement its position as the global leader in early to moderate glaucoma treatment intervention.”
The business will trade as “Ellex iScience, Inc.” Production of the iTrack 250 will continue at the facility at Menlo Park in San Francisco, and the expansion of the canaloplasty clinical training team will commence immediately in order to better support existing and new customers, the news release said.